Gerhard Koenig
Director/Board Member at VIGIL NEUROSCIENCE, INC.
Net worth: - $ as of 2024-03-30
Gerhard Koenig active positions
Companies | Position | Start | End |
---|---|---|---|
VIGIL NEUROSCIENCE, INC. | Director/Board Member | 2020-11-30 | - |
Independent Dir/Board Member | 2020-11-30 | - | |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | Director/Board Member | 2018-01-31 | - |
Chief Executive Officer | 2018-01-31 | - | |
Founder | 2018-01-31 | - | |
President | 2018-01-31 | - | |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | 2021-12-31 | - |
Career history of Gerhard Koenig
Former positions of Gerhard Koenig
Companies | Position | Start | End |
---|---|---|---|
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Consultant / Advisor | 2017-02-28 | 2020-12-30 |
Quartet Medicine, Inc.
Quartet Medicine, Inc. BiotechnologyHealth Technology Quartet Medicine, Inc. is a biotechnology company that develops treatments for chronic pain and inflammation by restoring tetrahydrobiopterin homeostasis inneuronal and inflammatory cells. Its drug discovery efforts are fully structurally enabled and are focused on demonstrating changes in BH4-related biomarkers that correlate with drug pharmacokinetics and efficacy in preclinical animal models. The company was founded by Kevin Pojasek, Kai Johnsson, and Clifford Woolf in 2013 and is headquartered in Cambridge, MA. | Chief Executive Officer | 2016-05-31 | 2017-10-30 |
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Private Equity Investor | 2003-01-31 | 2016-05-30 |
Corporate Officer/Principal | 2003-01-31 | 2016-05-30 |
Training of Gerhard Koenig
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Statistics
International
United States | 7 |
Germany | 2 |
Operational
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Consultant / Advisor | 2 |
Sectoral
Health Technology | 6 |
Finance | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
VIGIL NEUROSCIENCE, INC. | Health Technology |
Private companies | 5 |
---|---|
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Quartet Medicine, Inc.
Quartet Medicine, Inc. BiotechnologyHealth Technology Quartet Medicine, Inc. is a biotechnology company that develops treatments for chronic pain and inflammation by restoring tetrahydrobiopterin homeostasis inneuronal and inflammatory cells. Its drug discovery efforts are fully structurally enabled and are focused on demonstrating changes in BH4-related biomarkers that correlate with drug pharmacokinetics and efficacy in preclinical animal models. The company was founded by Kevin Pojasek, Kai Johnsson, and Clifford Woolf in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Gerhard Koenig
- Experience